Challenge:

A medium size company with a novel drug in late-stage development for a neurological indication was getting behind on developing a scientific platform and a scientific narrative for the product, due to a). insufficient staffing of the medical team supporting the drug in development; b) lack of internal expertis...

Challenge

In 2021, a midsize Pharma company was planning to update its Medical Affairs structure and practices, in order to keep up (and possibly get ahead of) the changes, accelerated by the pandemic, in customer needs and medical affairs priorities, strategies, activities and methods. The goal of the project was to info...

Challenge:

The Head of Medical Affairs (MA) in a midsize company was not satisfied with the level of collaboration between his organization and commercial colleagues who did not fully recognize the value of the MA contribution to the success of the company. The goal of the project was to understand and address the root ca...

A small biopharmaceutical company had successfully completed proof-of-concept studies in the steps to develop therapeutics for the treatment of neurological conditions, including Traumatic Brain Injury (TBI), Repeat Concussion (Chronic traumatic encephalopathy or CTE) and Stroke. The company contracted Coolmeen Consulting for the development of ...